Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies
American Society of Clinical Oncology Educational Book · 2026
DOI: 10.1200/edbk-26-518934 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026. Verfasst von Udhayvir S Grewal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Precision Medicine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 135 Literaturangaben.
Abstract (Originalsprache)
Neuroendocrine neoplasms (NENs) represent a heterogeneous group of malignancies ranging from relatively indolent well-differentiated neuroendocrine tumors (NETs) to more aggressive poorly differentiated neuroendocrine carcinomas (NECs). The advent of somatostatin receptor (SSTR)–targeting therapies, particularly radioligand therapy (RLT), has transformed the therapeutic landscape of NETs. Ongoing efforts are aimed at maximizing the therapeutic benefit of RLT and include retreatment and combination strategies as well as novel α-emitter–based radiopharmaceuticals. The increasing use of molecular profiling has led to the identification of recurrent canonical alterations in pancreatic NETs, including in MEN1 , ATRX / DAXX , PI3K/Akt/mTOR, and angiogenic signaling pathways, facilitating the development of effective targeted therapies. However, despite the addition of newer targeted therapies to the therapeutic armamentarium, resistance remains inevitable and highlights the need for improved predictive markers to inform therapy sequencing and novel biomarker-selected therapies. In addition, the development of novel therapeutic strategies including SSTR antagonists, nonpeptide drug conjugates, and novel radiopharmaceutical constructs highlights the potential of biomarker-informed therapies in this space. By contrast, treatment options for NECs remain limited, with modest therapeutic benefit of platinum-based chemotherapy. The identification of delta-like ligand 3 (DLL3) as a therapeutic target in high-grade NENs has led to the development of novel targeted therapies such as T-cell engagers, which have demonstrated promising activity in early phase clinical trials. In addition, other DLL3-targeting agents such as antibody-drug conjugates, trispecific engagers, and cellular therapies remain under investigation. Collectively, these advances underscore the potential of biomarker-informed treatment approaches to personalize treatment decisions and improve long-term outcomes across the NEN spectrum.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
- Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
- Division of Hematology/Oncology, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
- Division of Molecular Imaging and Therapy, Oregon Health & Science University, Portland, OR.
- Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN.
- Department of Medical Oncology, Sunnybrook Health Sciences Center/Odette Cancer Center, Toronto, ON, Canada.
Zitieren
APA
Grewal, U. S., Shaheen, S., Zhen, D. B., Mittra, E. S., Halfdanarson, T. R., Singh, S., & Chan, J. A. (2026). Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk-26-518934
Vancouver
Grewal US, Shaheen S, Zhen DB, Mittra ES, Halfdanarson TR, Singh S, et al. Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies. American Society of Clinical Oncology Educational Book. 2026. doi:10.1200/edbk-26-518934
BibTeX
@article{Grewal2026,
author = {Grewal, Udhayvir S and Shaheen, Shagufta and Zhen, David B and Mittra, Erik S and Halfdanarson, Thorvardur R and Singh, Simron and Chan, Jennifer A},
title = {Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies},
journal = {American Society of Clinical Oncology Educational Book},
year = {2026},
doi = {10.1200/edbk-26-518934}
}
EUVIMED